The company, a subsidiary of Interneuron Pharmaceuticals, also of Lexington, said the trials are the first beta blocker studies aimed at measuring the impact of the drug on mortality in congestive heart failure. * Cypros Pharmaceutical Corp., of Carlsbad, Calif., said its common stock (CYPR) and redeemable Class B warrants are listed on the NASDAQ National Market System. * Paracelsian Inc., of Ithaca, N.Y., said initial screenings of six Chinese medicinal compounds indicate that four have anti

The company, a subsidiary of Interneuron Pharmaceuticals, also of Lexington, said the trials are the first beta blocker studies aimed at measuring the impact of the drug on mortality in congestive heart failure. * Cypros Pharmaceutical Corp., of Carlsbad, Calif., said its common stock (CYPR) and redeemable Class B warrants are listed on the NASDAQ National Market System. * Paracelsian Inc., of Ithaca, N.Y., said initial screenings of six Chinese medicinal compounds indicate that four have anti

Each $8 unit consists of two shares of common stock and a warrant to purchase one share for $5. * Somatogen Inc., of Boulder, Colo., presented data showing its recombinant human hemoglobin delivers oxygen to tissues for use in energy production as effectively as whole blood. * Univax Biologics Inc., of Rockville, Md., started a Phase II trial of HyperGAM+CF, a specific polyclonal designed to prevent and treat recurring acute lung infections in cystic fibrosis patients. * VIMRx Pharmaceuticals

Health Script, a contract mail service pharmacy, generated revenues in 1994 of about $8 million. * Inhale Therapeutic Systems, of Palo Alto, Calif., raised $8 million through a public offering of 1 million shares of common stock

The units equal one share of common stock and one warrant redeemable at $7 per share. * Quintiles Transnational Corp., of Research Park Triangle, N.C., established a subsidiary in Singapore, Quintiles East Asia Pte

Each warrant is redeemable for one share of common stock at $4.75

The company also registered with the Securities and Exchange Commission to sell 1 million shares of newly issued common stock

The preferred stock is convertible into common stock at an effective price of $3.069 per share of common, or 85 percent of the stock's market value at conversion, whichever is lower. * Genelabs Technologies Inc., of Redwood City, Calif., completed a study in primates demonstrating the feasibility of its prototype hepatitis E vaccine, GL438...The preferred stock is convertible into common stock at an effective price of $3.069 per share of common, or 85 percent of the stock's market value at

The company said it intends to test the drug for the treatment of solid tumor cancers, such as brain tumors (glioblastoma) and ovarian cancer. * Neoprobe Corp., of Dublin, Ohio, citing unfavorable market conditions, has postponed a proposed public offering of 1.1 million shares of common stock

The agreement calls for Landmark Genetics to receive an undisclosed amount of cash and Alta shares of common stock. * biosys Inc., of Palo Alto, Calif., is acquiring Crop Genetics International, of Columbia, Md., for 3.5 million biosys stock shares in a merger of biopesticide companies...Under the agreement, biosys will trade one share of its stock for 5.25 shares of Crop Genetics common stock and an additional one share of biosys for 1.49 shares of Crop Genetics preferred stock. (c) 1997

They can exercise them until Dec. 9 and receive one-half of a Class B warrant and 1.175 shares of common stock upon payment of about $9.25 per Class A warrant exercised. * Advanced Tissues Sciences Inc., of La Jolla, Calif., received FDA approval for a supplement to its investigational device exemption to begin a pivotal trial of Dermagraft-Transitional Covering in severely burned patients. * Alamar Biosciences Inc., of Sacramento, Calif., an in vitro diagnostics testing company, completed a

They can exercise them until Dec. 9 and receive one-half of a Class B warrant and 1.175 shares of common stock upon payment of about $9.25 per Class A warrant exercised. (c) 1997 American Health Consultants

The drug is the second of five allergy therapies to enter clinical trials. * ImmuCell Corp., of Portland, Maine, said it plans to repurchase nearly 343,000 shares of its common stock held by Cambridge Biotech Corp., of Worcester, Mass., for $308,500

It refused to provide additional details to BioWorld. * Abaxis Inc., of Sunnyvale, Calif., has raised $9.4 million through the sale of 2.35 million shares of common stock

The agreement covers exclusive rights to all countries, except Canada and the U.K. Abaxis Inc., of Sunnyvale, Calif., has raised $9.4 million through the sale of 2.35 million shares of common stock

The $81,000 grant will aid in development of synthetic muscle-specific gene expression systems to provide high levels of cell-specific gene expression. * ImmunoTherapeutics Inc., of Fargo, N.D., said it repurchased 629,624 shares of its common stock and 412,953 1997 warrants for $300,000. (c) 1997 American Health Consultants

Applied DNA Systems Inc., of Warwick, R.I., has registered with the Securities and Exchange Commission to sell 700,000 shares of common stock

Dura Pharmaceuticals Inc., of San Diego, filed a registration statement for a public offering of 2.5 million shares of common stock, 2.25 million of which will be offered by the company

Instead, the common stock (ARIA) and warrants (ARIAW) will begin trading separately on NASDAQ...ARIAD issued more than 2 million warrants and an equal number of shares of common stock during the company's initial public offering May 20. * Inflazyme Pharmaceuticals Ltd., of Vancouver, Canada, plans to raise $60,000 through the private placement of 100,000 shares at 60 cents per share